Skip to main content
Clinical Trials/NCT06288074
NCT06288074
Recruiting
Not Applicable

Diagnosis and Treatment Strategy Optimization of Severe Pneumonia Based on Multi-omics Data Integration

Capital Medical University1 site in 1 country300 target enrollmentMarch 10, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Severe Community-acquired Pneumonia
Sponsor
Capital Medical University
Enrollment
300
Locations
1
Primary Endpoint
Hospital mortality
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Severe community-acquired pneumonia still has a high incidence and mortality, but the molecular mechanism and prognostic biomarkers of severe community-acquired pneumonia caused by different pathogens are still unclear, and the best treatment strategy has not been determined. Based on this, this project intends to take patients with severe community-acquired pneumonia caused by different pathogens as the research object, explore the molecular mechanism of severe community-acquired pneumonia from multiple angles, integrate relevant research data to evaluate the rationality of initial empirical medication, and lay the foundation for precise treatment of severe pneumonia. The research results will help to develop a new rapid and accurate target for clinical diagnosis and efficacy evaluation of severe pneumonia, and build a precise treatment system for severe pneumonia.

Registry
clinicaltrials.gov
Start Date
March 10, 2024
End Date
December 31, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Capital Medical University
Responsible Party
Principal Investigator
Principal Investigator

Zhaohui Tong

Clinical Professor

Capital Medical University

Eligibility Criteria

Inclusion Criteria

  • Age\> 18 years old
  • Clinical diagnosis of community-acquired pneumonia

Exclusion Criteria

  • Pregnancy, perinatal and lactating women
  • Combined immunosuppressive diseases: such as HIV, solid organ transplantation, solid organ/hematologic malignant tumor chemotherapy, rheumatic diseases or glomerular diseases need to take hormone/immunosuppressant therapy
  • Combined blood system diseases: such as leukemia reactions, aplastic anemia, neutropenia or deficiency of granulocytes, previous bone marrow/stem cell transplantation

Outcomes

Primary Outcomes

Hospital mortality

Time Frame: during hospitalization (up to day 14)

Secondary Outcomes

  • Length of ICU stay(during hospitalization (up to day 14))
  • Expense during hospitalization(during hospitalization (up to day 14))
  • Cause of death(during hospitalization (up to day 14))
  • Length of stay(during hospitalization (up to day 14))

Study Sites (1)

Loading locations...

Similar Trials